A pathway blocks the decay of the naive embryonic stem cell program 6, 14 . By regulating fetal neural stem and progenitor cells, m 6 A also plays a critical role in embryonic neurogenesis 15, 16 . The role of m 6 A in the haematopoietic system is emerging. Using zebrafish as a model, it has been shown that m 6 A is required for endothelial-to-haematopoietic transition and the emergence of HSCs and progenitor cells 17 . Short-hairpin RNA (shRNA) knockdown of Mettl3 or Mettl14 in human HSCs and progenitor cells leads to myeloid differentiation in vitro 18, 19 . These studies show that m 6 A plays critical roles for HSC emergence and in vitro function, but its role in mammalian adult HSCs and haematopoiesis in vivo remains unclear. A regulates HSCs and haematopoiesis in vivo, we generated and validated a floxed allele of Mettl3 ( Supplementary  Fig. 1b) Supplementary Fig. 1b ). Efficient deletion in HSCs was achieved within 10 d after the last pIpC injection ( Supplementary Fig. 1c,d) . Complete blood count analyses revealed a significant decrease in platelet counts in Mx1-cre; Mettl3 fl/fl mice compared with pIpCtreated controls 10-14 d (short term) after the last pIpC injection (Fig. 1a,b and Supplementary Fig. 2a ). Recent work in the field has proposed that platelets can be directly generated from HSCs 21, 22 . The platelet phenotype raises the possibility that m 6 A may regulate HSCs. The same phenotype persisted two to three months after the last pIpC injection (Fig. 1a,b and Supplementary Fig. 2a) . By four months, the white blood cell counts were also significantly 
, but the mechanisms that control balanced self-renewal and differentiation are poorly understood. Transcriptional, translational and epigenetic regulators have been shown to critically regulate HSC function 1 . Whether other molecular mechanisms also regulate HSCs is unclear. A) is a modified base found in eukaryotic messenger RNA 3 . This modification of adenosine is abundant and functions as an epitranscriptomic regulator of target mRNAs through multiple mechanisms, including stability and translation efficiency 4 . A methyltransferase complex, composed of methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), Wilms-tumour associated protein (WTAP) and other accessory proteins, deposits m 6 A onto mRNAs 5 . METTL3 is the essential catalytic component of the complex [6] [7] [8] [9] . It has been shown that m 6 A impacts fundamental cellular processes, including DNA damage repair 10 , meiosis 11 and the circadian clock 12 . Transcriptomewide mapping of m 6 A modification has revealed cell-type-specific methylation targets, suggesting that m 6 A regulates cell-type-specific processes 13 . Interestingly, m 6 A has been shown to impact the fate of stem and progenitor cells. Disruption of the m 6 A pathway blocks the decay of the naive embryonic stem cell program 6, 14 . By regulating fetal neural stem and progenitor cells, m 6 A also plays a critical role in embryonic neurogenesis 15, 16 . The role of m 6 A in the haematopoietic system is emerging. Using zebrafish as a model, it has been shown that m 6 A is required for endothelial-to-haematopoietic transition and the emergence of HSCs and progenitor cells 17 . Short-hairpin RNA (shRNA) knockdown of Mettl3 or Mettl14 in human HSCs and progenitor cells leads to myeloid differentiation in vitro 18, 19 . These studies show that m 6 A plays critical roles for HSC emergence and in vitro function, but its role in mammalian adult HSCs and haematopoiesis in vivo remains unclear.
Results

Deletion of Mettl3 disrupts haematopoiesis and leads to the accumulation of HSCs.
We performed quantitative real-time PCR (qPCR) analysis to assess the expression of Mettl3 in the haematopoietic system. Mettl3 transcripts were expressed at levels that were approximately 4.5-fold higher in CD150
HSCs compared with whole bone marrow cells ( Supplementary  Fig. 1a ), suggesting that METTL3-mediated m 6 A may regulate the function of HSCs.
To test whether m 6 A regulates HSCs and haematopoiesis in vivo, we generated and validated a floxed allele of Mettl3 ( Supplementary  Fig. 1b ) and crossed it with Mx1-cre 20 to generate Mx1-cre; Mettl3 fl/fl mice. We conditionally deleted Mettl3 from the adult haematopoietic cells by intraperitoneally injecting polyinosinic-polycytidylic acid (pIpC) into six-to eight-week-old Mx1-cre; Mettl3 fl/fl mice ( Supplementary Fig. 1b ). Efficient deletion in HSCs was achieved within 10 d after the last pIpC injection ( Supplementary Fig. 1c,d ). Complete blood count analyses revealed a significant decrease in platelet counts in Mx1-cre; Mettl3 fl/fl mice compared with pIpCtreated controls 10-14 d (short term) after the last pIpC injection (Fig. 1a,b and Supplementary Fig. 2a ). Recent work in the field has proposed that platelets can be directly generated from HSCs 21, 22 . The platelet phenotype raises the possibility that m 6 A may regulate HSCs. The same phenotype persisted two to three months after the last pIpC injection (Fig. 1a,b and Supplementary Fig. 2a ). By four months, the white blood cell counts were also significantly 
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NAtuRe Cell BIOlOgY reduced, with an altered white blood cell distribution ( Fig. 1a and Supplementary Fig. 2b ). These data suggest that m 6 A is required for haematopoiesis.
The deletion of Mettl3 led to a significant reduction in bone marrow cellularity (Fig. 1c) , but not spleen cellularity 10-14 d after the last pIpC injection (Fig. 1d,e) . However, by 2-4 months after the last pIpC injection, in addition to a significant reduction in bone marrow cellularity, the spleen size and cellularity were significantly increased with a distortion of cell-type distribution (Fig. 1c-e and Supplementary Fig. 2c ). The spleens contained more HSCs in Mx1-cre; Mettl3 fl/fl mice compared with controls (Fig. 1f) . These data are suggestive of extramedullary haematopoiesis after the loss of m 6 A. In the bone marrow, Lin − Sca1 + cKit + (LSK) haematopoietic progenitors (Fig. 1g) and HSCs ( Fig. 1h and Supplementary Fig. 2d,e) were significantly increased at all of the time points examined. The HSC pool uniquely expanded over time from 10-14 d to 4 months after the last pIpC injection, progressing from a 3-fold to a 17-fold increase in HSC frequency ( Fig. 1h and Supplementary Fig. 2d,e) . In contrast, the frequency of CD150 − CD48
− LSK multipotent progenitors (MPPs) was not significantly increased, whereas the frequency of CD150 − CD48
+ LSK progenitors was only modestly increased ( Fig. 1i and Supplementary Fig. 2f ). The frequency of CD150 +
CD48
+ LSK megakaryocyte-skewed progenitors was significantly increased ( Supplementary Fig. 2f ), suggesting that there is also an effect on the megakaryocyte lineage. Thus, at the top of the haematopoietic hierarchy, the loss of m 6 A preferentially leads to HSC accumulation. We also examined other haematopoietic progenitors in the bone marrow. mice compared with controls until four months after the last pIpC treatment when there was a modest decrease in the granulocyte/ macrophage progenitor and a modest increase in megakaryocytic/ erythroid progenitor frequencies ( Supplementary Fig. 2g ). There was a significant increase in Lin − Sca1 − cKit + CD150 + CD41 + megakaryocyte progenitors and CD41
+ megakaryocytic cells in the bone marrow (Fig. 1j,k) , suggesting that the reduction in platelet counts (Fig. 1b) is due to a differentiation defect in the megakaryocyte lineage. These data suggest that a loss of Mettl3 preferentially impacts HSCs, with effects on the megakaryocyte lineage.
Deletion of Mettl3 preferentially blocks HSC differentiation.
Haematopoietic stem cells from pIpC-injected Mx1-cre; Mettl3 fl/fl mice did not incorporate more BrdU (Fig. 2a) but exhibited a slight increase in cell death (Fig. 2b) , suggesting that the accumulation of HSCs may be the result of blocked differentiation rather than enhanced self-renewal. The Mettl3-deficient HSCs did not have elevated levels of reactive oxygen species or γH2Ax staining ( Supplementary Fig. 2h,i) . Consistent with an HSC-differentiation defect, pIpC-injected Mx1-cre; Mettl3 fl/fl mice had lower survival rates compared with controls when challenged with a myeloablative agent, 5-fluorouracil (Fig. 2c) .
We performed methylcellulose assays to directly assess the differentiation potential of Mettl3-deficient HSCs. Single HSCs from pIpC-treated Mx1-cre; Mettl3 fl/fl or control mice were directly sorted into methylcellulose, which supports myelo-erythroid differentiation in vitro 23, 24 . Significantly fewer Mettl3-deficient HSCs formed colonies compared with control HSCs, particularly multipotent granulocyte, erythrocyte, monocyte and megakaryocyte colonies (CFU-GEMM) (Fig. 2d) . The vast majority of the colonies formed by Mettl3-deficient HSCs were significantly smaller compared with those formed by control HSCs (Fig. 2e and Supplementary Fig. 3a) . Flow cytometry analyses on cells from these colonies showed that Mettl3-deficient HSCs failed to differentiate, whereas control HSCs readily differentiated into Gr1 + and Mac1 + myeloid cells (Fig. 2f,h ). A few colonies formed by Mettl3-deficient HSCs were of normal size and genotyping revealed that these colonies had escaped complete Mettl3 deletion ( Supplementary Fig. 3b,c) . Mettl3-deficient HSCs in spleens also failed to differentiate ( Supplementary Fig. 3d ).
In contrast, when Mettl3-deficient whole bone marrow cells were plated into methylcellulose, the colonies that formed were similar in number, size and types compared with controls (Fig. 2g) 
CD48
+ LSK) into methylcellulose. They formed normal numbers of colonies, similar in size and type compared with controls ( Supplementary Fig. 3e ). Flow cytometry analysis confirmed that these colonies contained normal numbers of differentiated cells ( Fig. 2h and Supplementary Fig. 3f ). Together, these data suggest that a loss of Mettl3 preferentially leads to a differentiation block in HSCs but not in restricted progenitors in vitro.
Deletion of Mettl3 leads to cell-intrinsic HSC reconstitution and differentiation defects in vivo. To test whether a loss of Mettl3 leads to HSC defects in vivo, we performed competitive reconstitution assays by transplanting 500,000 bone marrow cells from either Mx1-cre; Mettl3 fl/fl or control mice 10 d after the last pIpC injection along with 500,000 competing wild-type bone marrow cells into lethally irradiated recipient mice. The Mettl3-deficient bone marrow cells contributed significantly lower levels of overall, myeloid, B and T lineage cells in peripheral blood and a trend towards lower levels of HSCs in bone marrow compared with controls ( Fig. 3a and Supplementary Fig. 4a ). Genotyping analysis of sorted residual donor-derived peripheral blood cells demonstrated that these residual cells escaped complete Mettl3 deletion ( Supplementary Fig. 4b ). To specifically test whether HSCs were functionally defective, we sorted and transplanted Mettl3-deficient and control HSCs along with wild-type competing bone marrow cells into lethally irradiated mice. Although control HSCs readily reconstituted the recipient mice in all major haematopoietic lineages, Mettl3-deficient HSCs failed to give any discernable reconstitution ( Fig. 3b and Supplementary Fig. 4c ). These data suggest that Mettl3-deficient HSCs are defective in reconstituting recipient mice.
To determine whether Mettl3 is required cell-intrinsically for HSC function, we transplanted either Mx1-cre; Mettl3 fl/fl or control bone marrow cells, without pIpC treatment, along with wild-type competitor bone marrow cells into irradiated recipient mice. We waited at least eight weeks after transplantation for stable bone marrow chimaerism to be established. Mettl3 was then deleted by pIpC injection and the donor-derived peripheral blood cells were monitored over time. The overall reconstitution by Mettl3-deficient bone marrow cells was significantly lower than controls (Fig. 3c) . The reconstitution defects were mainly in the myeloid and B lineages, but not in the T cell lineages (Fig. 3c) , which is consistent with the slow turnover kinetics of T cells in adults in vivo. After 16 weeks, the recipient mice were killed and analysed for the frequencies of donor-derived bone marrow HSCs and haematopoietic progenitors. Mettl3-deficient HSCs were present at similar levels compared with control HSCs (Fig. 3d) , suggesting that HSC self-renewal is largely normal. However, these HSCs generated gradually fewer mature haematopoietic cells along the differentiation hierarchy (Fig. 3d) . Consistent with the depletion of donor-derived myeloid cells in peripheral blood (Fig. 3c ), very few common myeloid progenitors, granulocyte/macrophage progenitors and megakaryocytic/ erythroid progenitors were derived from Mettl3-deficient HSCs (Fig. 3d) . Genotyping of sorted donor-derived cells in recipient mice showed that these residual cells escaped complete Mettl3 deletion ( Supplementary Fig. 4d ). These data suggest that Mettl3 is required for HSC differentiation in vivo.
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We also conditionally deleted Mettl3 from haematopoietic cells using Rosa26-creER 25 . We non-competitively transplanted bone marrow cells from Rosa26-creER; Mettl3 fl/fl mice into irradiated recipient mice and then deleted Mettl3 by administering tamoxifen. The deletion of Mettl3 led to a significantly higher frequency of HSCs in the recipient mice ( Supplementary Fig. 4e ) recapitulating the Mx1-cre; Mettl3 fl/fl model (Fig. 1h) . We also competitively transplanted Rosa26-creER; Mettl3 fl/fl bone marrow cells together with recipient-type bone marrow cells and waited at least eight weeks after transplantation for stable bone marrow chimaerism before administering tamoxifen. Tamoxifen-induced deletion of Mettl3 also led to a significant reduction in reconstitution activity ( Supplementary Fig. 4f ), similar to Mx1-cre; Mettl3 fl/fl mice (Fig. 3c ).
Mettl3 is not required for myelopoiesis. Fig. 4g ). Six-to eight-week-old Lysm-cre; Mettl3 fl/fl mice had normal peripheral blood counts (Fig. 4a ,b and Supplementary Fig. 4h ), bone marrow and spleen cellularity ( Fig. 4c and Supplementary Fig. 4i ), and frequencies of myeloid cells in the bone marrow and spleens (Fig. 4d) .
Mettl3-deficient bone marrow myeloid cells from Lysm-cre; Mettl3 fl/fl mice formed macrophages with normal morphology ( Supplementary Fig. 4j ). When challenged with lipopolysaccharide, these macrophages showed normal upregulation of the inflammatory cytokines Tnfa, Il1b and Il6 (Fig. 4e) . Mettl3-deficient bone marrow-derived macrophages also displayed a robust engulfing activity, similar to controls (Fig. 4f) . These data suggest that Mettl3 ; the samples were from independent recipients of 2 independent donor pairs from 2 experiments). c, Donor whole bone marrow cells (500,000) from untreated Mx1-cre; Mettl3 fl/fl or controls with 500,000 competitor cells were transplanted into lethally irradiated recipient mice. The recipients were treated with pIpC after stable peripheral blood chimaerism was established (top). is not required for the maintenance or function of mature myeloid cells and the observed reconstitution deficiencies (Fig. 3c) are a consequence of HSC differentiation defects. Furthermore, these data provide conclusive evidence that there is a stage-specific dependence on Mettl3 and m A-tagged mRNA immunoprecipitation sequencing (meRIP-seq) method to analyse the m 6 A methylome of 2,000 freshly sorted wild-type HSCs from six-to eight-week-old mice ( Supplementary Fig. 5a,b) . Compared with the unbound fraction, 2,073 transcripts (false discovery rate (FDR) < 0.05 and fold > 2) were significantly enriched in the m 6 A antibody-bound fraction and were defined as high-confidence m 6 A targets (Fig. 5a,b . The statistics were computed using GSEA and controlled for multiple comparisons by FDR. e, Cumulative distribution of log 2 gene expression ratios of Mettl3-deficient or control mice. The genes were categorised as m 6 A and non-m 6 A by meRIP-seq. Inset, the box plot of the log 2 fold change in expression of non-m 6 A and m 6 A targets in HSCs. The plot displays the mean, standard deviation and interquartile range. The P value was determined by a two-sided Kolmogorov-Smirnov test. All sequencing data were from n = 3 biologically independent animals for both the control and A modification of these targets depended acutely on METTL3 ( Supplementary Fig. 5c,d ). The lack of complete elimination of m 6 A may be due to residue METTL3 protein, slow turnover of some target mRNAs or antibody detection of the cap region m 6 Am, which, unlike m Fig. 5f ). Consistent with the differentiation defects observed in Mettl3-deficient HSCs (Figs. 1-4) , we observed significant enrichment of genes associated with haematopoietic differentiation 
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NAtuRe Cell BIOlOgY (Supplementary Fig. 5e ). These data suggest that m 6 A regulates HSC differentiation by directly targeting haematopoietic differentiation pathways. Several known HSC regulators were identified as major targets of m 6 A, including Myc, Junb and Tet2 (Fig. 5b) . More importantly, the enrichment of these genes in the m 6 A-bound fraction was significantly decreased when Mettl3 was deleted from HSCs, suggesting that the m 6 A modification of these genes is dependent on METTL3 (Fig. 5c and Supplementary Fig. 5c,d ).
Deletion of Mettl3 leads to a loss of HSC identity without drastic alterations of the transcriptome. To further understand the molecular mechanisms underpinning the functional defects of Mettl3-deficient HSCs, we performed RNA sequencing (RNA-seq) analysis on Mettl3-deficient HSCs using Smart-seq2 (ref. 27 ). Significant differences in expression were observed for 830 genes (P < 0.05; Supplementary Table 2 ). Only seven genes showed significant expression differences (FDR < 0.05) between Mettl3-deficient and control HSCs after stringent analysis with correction for multiple comparisons ( Supplementary Fig. 6a and Supplementary Table 2 ). As expected, Mettl3 was one of the most significantly downregulated genes in Mettl3-deficient HSCs (Supplementary Fig. 6a ). Gene set enrichment analysis (GSEA) 28 showed that Mettl3 deficiency predominantly led to a loss of expression of HSC-identityassociated genes defined by previous publications [29] [30] [31] ( Fig. 5d and Supplementary Fig. 6b ). These data suggest that METTL3-mediated m 6 A modestly altered HSC identity without profoundly impacting global mRNA levels.
It has been demonstrated that m 6 A negatively regulates target mRNA stability in several cell types 4 . We thus assessed whether m 6 A targets were upregulated in Mettl3-deficient HSCs. Of the 384 upregulated genes in Mettl3-deficient HSCs, 95 were m 6 A targets (P < 0.05 and fold change > 1.2; Supplementary Table 2 and Supplementary Fig. 6c ). However, none of the seven high-confidence differentially expressed genes (FDR < 0.05; Supplementary Table 1 and Supplementary Fig. 6a ) were high-confidence m 6 A targets. Compared with non-m 6 A targets, the transcripts of m 6 A targets had slightly increased abundance in Mettl3-deficient HSCs (Fig. 5e) . Together, these data suggest that although m 6 A may directly control the transcript levels of some genes, it predominantly regulates target mRNA post-transcriptionally in HSCs.
Myc is a direct target of m 6 A in HSCs. It has been shown that MYC protein levels are very low in HSCs and are upregulated following differentiation through post-transcriptional mechanisms 32, 33 . Furthermore, deletion of Myc blocks HSC differentiation, whereas higher levels of MYC protein promote HSC differentiation 32, 34 . Prompted by the observations that Myc is a major determinant of HSC differentiation and the phenotypic similarity between Myc and Mettl3 conditional knockout mice (accumulation of HSCs and blockage of differentiation), we investigated whether Myc is a direct target of m 6 A in HSCs. Our meRIP-seq analyses revealed that Myc was one of the top candidates highly enriched in m 6 A antibody-bound fraction compared with the unbound fraction (~30 fold enrichment, FDR = 3.96 × 10 −15 ; Fig. 5b ,c) in a Mettl3-dependent manner (Fig. 5c and Supplementary Fig. 5c,d) . We confirmed these meRIP-seq data using qPCR on independent samples (Fig. 6a) . Interestingly, Myc transcript levels were not significantly changed in Mettl3-deficient HSCs compared with controls ( Supplementary Fig. 6d ). Using several previously published Myc-target gene sets 35, 36 , GSEA revealed a significant decrease in Myc-target gene signatures in Mettl3-deficient HSCs (Fig. 6b and Supplementary Fig. 6e ), suggesting that m 6 A may primarily regulate Myc mRNA translation.
In vivo Myc protein levels can be directly measured by a knockin Myc-green fluorescent protein (GFP) translational reporter 37 . To assess the impact of Mettl3 deletion on the level of Myc protein in HSCs, we generated Mx1-cre; Mettl3 fl/fl ; Myc-GFP mice. Consistent with previous publications 32, 33 , HSCs expressed low levels of MYC-GFP compared with haematopoietic progenitors at steady state (Fig.  6c) . The deletion of Mettl3 led to a modestly significant reduction of MYC-GFP in HSCs (Fig. 6c) . Remarkably, following activation to differentiate, Mettl3-deficient HSCs failed to upregulate MYC-GFP, whereas control HSCs could readily do so (Fig. 6d) . Mettl3 deletion did not lead to changes in HSC Myc transcript levels under the activation condition (Supplementary Fig. 6d ). Given that m 6 A primarily regulates target mRNA stability and translation 5, 38 , these data suggest that m 6 A is required for Myc mRNA translation in HSCs, particularly following differentiation.
We tested whether forced expression of Myc can rescue the HSC differentiation defects caused by the deletion of Mettl3. We transduced Mettl3-deficient HSCs with Myc-expressing or control retroviruses ( Fig. 6e and Supplementary Fig. 6f ) and assessed their differentiation potential in vitro. Forced expression of Myc significantly rescued the differentiation defect of Mettl3-deficient HSCs compared with controls (Fig. 6e) . These data indicate that Myc is one of the major functional targets of m 6 A in HSCs.
Discussion
We demonstrate that m 6 A is preferentially required for adult HSC differentiation in vivo and in vitro, but not mature myeloid cell maintenance or function. These results demonstrate that m 6 A is not a general cellular housekeeping mechanism, but rather a modification with specific roles in HSCs. Our results are in contrast to reports that show that m 6 A inhibits the differentiation of CD34
+ human haematopoietic progenitor cells in vitro 18, 19 . As those experiments were performed using shRNAs on cells of mixed populations of HSCs and progenitors in vitro, it is not clear what the effects on human HSCs are in vivo. Notably, we observed differences between HSCs and progenitors in their response to Mettl3 deletion ( Fig. 2 and Supplementary Fig. 3) , suggesting that the roles of m 6 A in HSCs and progenitors need to be assessed independently. Consistent with our data, Yao et al. recently showed that the conditional deletion of Mettl3 led to an accumulation of HSCs in the bone marrow while our paper was under review 39 . In contrast to its role in enabling HSC differentiation, m 6 A inhibits differentiation in acute myeloid leukaemia cells 18, 19, 40 . This surprising difference may reflect distinct mechanisms of action for m 6 A in leukaemic cells and HSCs, and suggests that it may be possible to develop m 6 A-targeted therapies against leukaemia cells without damaging HSC function. More work is needed to elucidate the differences between the role of m 6 A in leukaemic cells and in HSCs.
We found that HSC self-renewal and quiescence is largely intact after Mettl3 deletion (Figs. 2a and 3d) . Thus, it appears that m 6 A specifically regulates HSC differentiation. Epitranscriptional regulation mediated by m 6 A in HSCs may provide a fast and flexible mechanism to control mature blood cell output, allowing the organism to adapt to ever-changing physiological demands. Mettl3-deficient HSCs failed to establish bone marrow chimaera in transplantation ( Supplementary Fig. 4a,c) , suggesting that m 6 A may regulate HSC homing and/or engraftment, which will be of interest in future further investigations.
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Methods
Mice. Mx1-cre 20 , Lysm-cre 26 and Myc-GFP 37 mice were obtained from the Jackson Laboratory and maintained on a C57BL/B6 background. Rosa26-creER mice 25 were generated and provided by T. Ludwig at Columbia University. Mettl3 fl mice were generated by electroporation of a targeting vector (obtained from the Knockout Mouse Project Repository) into V6.5 embryonic stem cells. A correctly targeted embryonic stem cell clone, validated by PCR and Southern blot analysis, was identified and injected into BDF1 blastocysts and chimaeric mice were generated. The chimaeric mice were bred with C57BL/6 mice to obtain germline transmission. The resulting mice were crossed with Flpe mice 41 to remove the Neo cassette. These mice were backcrossed at least six times onto a C57BL/6 background before analysis. To induce Cre expression in Mx1-cre; Mettl3 fl/fl mice, six-to eight-weekold animals were intraperitoneally injected with 10 µg pIpC (GE or InvivoGen) in PBS every other day for five injections. The mice were analysed 10-14 d, 2-3 months or 4 months after the final injection, as indicated in each experiment. To induce Cre expression in Rosa26-CreERT2; Mettl3 fl/fl mice, the recipients were given 1 µg tamoxifen in 50 µl corn oil by gavage every other day for five doses. All of the mice were housed in specific pathogen-free, Association for the Assessment and Accreditation of Laboratory Animal Care-approved facilities at the Columbia University Medical Center. All protocols were approved by the Institute Animal Care and Use Committee of Columbia University. The study is compliant with all relevant ethical regulations regarding animal research.
Genotyping PCR primers. The following primers were used for genotyping: GTTGATGAAATTATCAGTACAATGGTTCTGA and GTAAAGAACAACTCTGGTTATCGTCATCG for the fl/fl and littermate control mice were treated with pIpC as previously described. Ten days after the last pIpC injection, the mice were intraperitoneally injected with 150 mg kg −1 5-fluorouracil weekly until death or experimental conclusion.
Complete blood counts. Peripheral blood was collected by tail-vein or cardiac puncture into EDTA-coated capillary tubes. The blood samples were analysed by Genesis (Oxford Science Inc).
Flow cytometry. Bone marrow cells were isolated by flushing the long bones or by crushing the long bones, pelvis and vertebrae with a mortar and pestle in Ca 2+ -and Mg
2+
-free HBSS medium with 2% heat-inactivated bovine serum. Splenic cells were obtained by crushing the spleens between two glass slides. The splenic and bone marrow cells were passed several times through a 25G needle and filtered through 70-μm nylon mesh. The following antibodies were used to perform HSC staining: lineage markers anti-CD2 (RM2-5), anti-CD3 (17A2), anti-CD5 (53-7.3), anti-CD8a (53-6.7), anti-B220 (6B2), anti-Gr1 (8C5), anti-Ter119); anti-Sca1 (E13-161.7); anti-cKit (2B8); anti-CD48 (HM48-1) and anti-CD150 (TC15-12F12.2). In addition, the following antibodies were used to perform haematopoietic progenitor staining as previously described 24 : lineage markers anti-CD2 (RM2-5), anti-CD3 (17A2), anti-CD5 (53-7.3), anti-CD8a (53-6.7), anti-B220 (6B2), anti-Gr1 (8C5), anti-Ter119; anti-Sca1 (E13-161.7); anti-cKit (2B8); anti-CD34 (RAM34); anti-FLT3 (A2F10); anti-CD16/32 (93) and anti-IL7Rα (A7R34).
Cell cycle, DNA damage, cell death and reactive oxygen species analysis. For BrdU incorporation analysis, mice were intraperitoneally injected with 0.1 mg kg
BrdU and maintained on 0.5 mg ml −1 BrdU water for 5 d before analysis. The frequency of BrdU + cells was determined by flow cytometry using an APC BrdU flow kit (BD Biosciences) as per the manufacturer's instructions. To measure γH2AX levels, the cells were stained for SLAM markers, fixed and permeabilized (BD Biosciences BrdU flow kit) and stained with anti-γH2AX (Biolegend, clone 2F3), followed by flow cytometry. Annexin V staining was performed using the Annexin V apoptosis detection kit APC (eBioscience) as per the manufacturer's instructions. Reactive-oxygen-species levels were measured by DCFDA staining (29-79-dichlorofluorescein diacetate; Thermo Fisher Scientific). After antibody staining, the cells were incubated with 10 µM DCFDA for 15 min at 37 °C, followed by flow cytometry.
Long-term competitive reconstitution assay. Adult recipient mice were lethally irradiated by a caesium 137 irradiator (JL Shepherd and Associates) at 300 rad min −1 with two doses of 540 rad (total 1,080 rad) delivered at least 2 h apart. Cells were transplanted by retro-orbital venous sinus injection of anaesthetized mice. Mice were transplanted with either 5 × 10 5 donor and 5 × 10 5 competitor bone marrow cells or 50 sorted donor HSCs and 3 × 10 5 competitor bone marrow cells, as indicated. The donor mice were either untreated or killed 10 d after pIpC treatment, as indicated. The recipient mice were temporarily maintained on antibiotic water (0.17 g l −1 Baytril) for 14 d after transplantation. Peripheral blood from recipient mice was analysed by flow cytometry at the indicated time points for at least 16 weeks after transplantation to assess the level of donor-derived blood lineages (donor chimaerism), including myeloid, B and T cells. For the posttransplantation Cre-induction experiments, the peripheral blood of the recipients was analysed over a minimum of two time points at least six-to-eight weeks after transplantation to ensure stable engraftment before treatment with pIpC (10 µg per mouse per dose for 5 doses) or tamoxifen (1 µg per mouse per dose for 5 doses). Blood was subjected to ammonium chloride potassium red cell lysis before antibody staining. Antibodies including anti-CD45.2 (104), anti-CD45.1 (A20), anti-CD3 (17A2), anti-B220 (6B2), anti-Gr1 (8C5) and anti-Mac1 (M1/70) were used to stain cells. fl/fl mice 10 d after pIpC treatment and plated into DMEM with 15% heat-inactivated fetal bovine serum, 100 ng ml −1 SCF, 10 ng ml −1 IL-3, 10 ng ml −1 IL-6 and 50 μM β-mercaptoethanol. The cells were transduced with at least 120 multiplicity of infection retrovirus particles in the presence of 8 μg ml −1 polybrene and spun at 1,400g for 1.5 h at 20 °C. The cells were then collected and plated in 1.5 ml methylcellulose culture medium and incubated at 37 °C for 9-12 d. Colonies were collected in bulk and resuspended in Ca2
Colony
+ -and Mg2
+ -free HBSS with 2% heat-inactivated bovine serum before staining with antibodies. The cells were then analysed by flow cytometry.
Macrophage culture and phagocytosis assay. One million whole bone marrow cells were plated in 12-well plates and cultured at 37 °C in DMEM (Thermo Fisher) supplemented with 10% fetal bovine serum (LifeTech) and 30% L929 supernatant. After 6 d, non-adherent cells were removed and macrophages were re-plated in fresh medium. Stimulation and phagocytosis assays were carried out on the seventh day.
For the stimulation assays, 1 μg ml −1 lipopolysaccharides (Sigma) were added to cells for 3 h. Stimulated and unstimulated control cells were harvested into TRIzol (Invitrogen) and RNA was isolated according to the manufacturer's instructions. The samples were reverse transcribed and subjected to qPCR, as previously described.
For the phagocytosis assays, cells were incubated for 1 h at 37 °C or 4 °C at a multiplicity of infection of 1∶50 with Fluoresbrite carboxylate microspheres (Polyscience) washed in PBS with 1% fetal bovine serum. Non-adherent cells and excess microspheres were removed by washing with DMEM before the macrophages were collected and analysed by flow cytometry.
qPCR. Cells were sorted directly into TRIzol. Total RNA was extracted according to the manufacturer's instructions. The total RNA was subjected to reverse transcription using SuperScript III (Invitrogen). Quantitative real-time PCR was run using SYBR green on a CFX Connect (Biorad) system. The RNA content of samples was normalized to β-actin. The primer sequences were: β-actin, GCTCTTTTCCAGCCTTCCTT and CTTCTGCATCCTGTCAGCAA; Mettl3, AAGGAGCCGGCTAAGAAGTC and TCACTGGCTTTCATGCACTC; Myc, TCTCCCCAAGGGAAGACGAT and TTGCTCTTCTTCAGAGTCGCT; Tnfa, GGAACTGGCAGAAGAGGCACTC and GCAGGAATGAGAAGAGGCTGAGAC; Il6, CCTCTGGTCTTCTGGAGTACC and ACTCCTTCTGTGACTCCAGC and Il1b, GCACTACAGGCT CCGAGATGAAC and TTGTCGTTGCTTGGTTCTCCTTGT.
MeRIP-qPCR. Poly(A)+ RNA was isolated from whole bone marrow cells or sorted HSCs using Dynabeads Oligo-(dT)25 magnetic beads (Thermo Fisher Scientific) according to the manufacturer's instructions. Anti-m 6 A antibody (1.25 μg; Synaptic Systems) was pre-bound to Protein A/G magnetic beads (Millipore) in IP buffer (20 mM Tris pH 7.5, 140 mM NaCl, 1% NP-40 and 2 mM EDTA) for 1 h. The sample RNA was incubated with antibody-bound Protein A/G beads for 2 h at 4 °C. The samples were washed twice in low-salt wash buffer (10 mM Tris pH 7.5 and 5 mM EDTA), twice with high-salt wash buffer (20 mM Tris pH 7.5, 1 M NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA) and twice with RIPA buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA). All of the wash solutions for each sample were collected as the 'unbound' fraction. RNA was eluted from the beads by incubating with 50 μl 20 mM N Last updated by author(s): Feb 7, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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RNAseq data from this study have been deposited to GEO with Access number GSE123527. DNA gel raw image data were included in the Supplementary Figure 7 .
Statistical source data were included in the Supplementary Table 3 .
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
